Abstract:Non‐alcoholic fatty liver disease (NAFLD) is an essential component of metabolic syndrome. Much evidence has demonstrated that the incidence of NAFLD is markedly increased in obese populations. In addition, adiposity and inflammation are two factors that critically contribute to the development and progression of hepatic steatosis and inflammatory damage in obesity‐associated NAFLD. While mediating the anti‐inflammatory activity of adenosine, the 2A receptor of adenosine (A2AR) also has a protective role in NAFLD. However, it remains largely unknown about the extent to which A2AR acts through altering adiposity vs. inflammation to protect against NAFLD. In the present study, the effects of A2AR deficiency on aspects of NAFLD were investigated in both obese mice and lean mice upon feeding wild‐type (WT) C57BL/6J mice and A2AR‐deficent mice a high‐fat diet (HFD) and/or a methionine‐ and choline‐deficient diet (MCD). Compared with low‐fat diet‐fed mice, HFD‐fed WT mice displayed overt hepatic steatosis and inflammation as indicated by increased proinflammatory signaling and cytokine expression. Furthermore, the severity of HFD‐induced hepatic steatosis and inflammation in A2AR‐deficient mice was much greater than that in WT mice, which was accompanied with increased body weight, adiposity, and adipose tissue infiltration of proinflammatory macrophages in HFD‐fed A2AR‐deficient mice. Unlike HFD‐fed mice, all MCD‐fed mice displayed lean phenotype due to a significant decrease in food intake. In the absence of adiposity, A2AR‐deficient mice still displayed a greater increase in the severity of hepatic steatosis and inflammation compared with WT mice. In an in vitro system, A2AR‐deficient macrophages showed an increase in proinflammatory responses compared with control cells. In addition, co‐culture of WT primary mouse hepatocytes with A2AR‐deficient macrophages caused significant increases in hepatocyte fat deposition and in hepatocyte proinflammatory responses compared with WT hepatocyte‐macrophage co‐cultures. Taken together, these results suggest that A2AR‐defiency‐associated inflammation is sufficient enough to bring about NAFLD aspects although A2AR deficiency can act through increasing both adiposity and inflammation to exacerbate NAFLD. Therefore, A2AR appears to protect against NAFLD mainly through its anti‐inflammatory activity.

Adipose ADM2 ameliorates NAFLD via promotion of ceramide catabolism

Deficiency of ADAR2 ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in obese mice

Adrenomedullin 2 Enhances Beiging in White Adipose Tissue Directly in an Adipocyte-autonomous Manner and Indirectly Through Activation of M2 Macrophages*

Adrenomedullin 2 Improves Early Obesity-Induced Adipose Insulin Resistance by Inhibiting the Class II MHC in Adipocytes.

Synergistic activation of AMPK by AdipoR1/2 agonist and inhibitor of EDPs–EBP interaction recover NAFLD through enhancing mitochondrial function in mice

Exacerbation of NAFLD in Both HFD‐fed Mice and MCD‐fed Mice by Adenosine 2A Receptor Deficiency

Adrenomedullin ameliorates palmitic acid-induced insulin resistance through PI3K/Akt pathway in adipocytes

Disruption of Adenosine 2A Receptor Exacerbates NAFLD Through Increasing Inflammatory Responses and SREBP1c Activity

ADAR2 deficiency ameliorates non‐alcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1

Adrenomedullin Attenuates Inflammation in White Adipose Tissue of Obese Rats Through Receptor‐Mediated PKA Pathway

Adiponectin receptor agonist ameliorates cardiac lipotoxicity via enhancing ceramide metabolism in type 2 diabetic mice

CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice

Adrenomedullin ameliorates the development of atherosclerosis in apoE−/− mice

AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis

Adiponectin Inhibits NLRP3 Inflammasome Activation in Nonalcoholic Steatohepatitis via AMPK-JNK/ErK1/2-NFκB/ROS Signaling Pathways

N-Acetyl Cysteine Ameliorates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease and Intracellular Triglyceride Accumulation by Preserving Mitochondrial Function

Adipose Lipocalin 2 overexpression protects against age-related decline in thermogenic function of adipose tissue and metabolic deterioration

Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway

Adiponectin inhibits palmitic acid-induced NLRP3 inflammasome activation in hepatocytes through AMPK-JNK/ErK1/2-NFκB/ROS signaling pathways

STUB1 increases adiponectin expression by inducing ubiquitination and degradation of NR2F2, thereby reducing hepatic stellate cell activation and alleviating non-alcoholic fatty liver disease

FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1